ATE277353T1 - Tau als marker für frühe schäden des zentralen nervensystems - Google Patents

Tau als marker für frühe schäden des zentralen nervensystems

Info

Publication number
ATE277353T1
ATE277353T1 AT99968716T AT99968716T ATE277353T1 AT E277353 T1 ATE277353 T1 AT E277353T1 AT 99968716 T AT99968716 T AT 99968716T AT 99968716 T AT99968716 T AT 99968716T AT E277353 T1 ATE277353 T1 AT E277353T1
Authority
AT
Austria
Prior art keywords
tau
marker
nervous system
cns
central nervous
Prior art date
Application number
AT99968716T
Other languages
English (en)
Inventor
Frank Hulstaert
Eugeen Vanmechelen
Hugo Vanderstichele
De Voorde Andre Van
Gool Stefaan Van
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE277353T1 publication Critical patent/ATE277353T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Devices That Are Associated With Refrigeration Equipment (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
AT99968716T 1998-09-08 1999-09-07 Tau als marker für frühe schäden des zentralen nervensystems ATE277353T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98870190 1998-09-08
PCT/EP1999/006592 WO2000014546A1 (en) 1998-09-08 1999-09-07 Tau as a marker for early cns damage

Publications (1)

Publication Number Publication Date
ATE277353T1 true ATE277353T1 (de) 2004-10-15

Family

ID=8237090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968716T ATE277353T1 (de) 1998-09-08 1999-09-07 Tau als marker für frühe schäden des zentralen nervensystems

Country Status (11)

Country Link
EP (1) EP1112500B1 (de)
JP (1) JP4624559B2 (de)
CN (2) CN1325491A (de)
AT (1) ATE277353T1 (de)
AU (1) AU772151B2 (de)
BR (1) BR9913112A (de)
CA (1) CA2340433A1 (de)
DE (1) DE69920487T2 (de)
ES (1) ES2229817T3 (de)
HK (1) HK1040429B (de)
WO (1) WO2000014546A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016655A1 (ja) 2002-08-14 2004-02-26 Mitsubishi Chemical Corporation 中枢性タウ蛋白質特異的抗体
NZ539734A (en) 2002-10-09 2011-07-29 Dmi Biosciences Inc Diagnosis and monitoring of inflammation, ischemia and appendicitis
JP5721426B2 (ja) 2007-04-05 2015-05-20 ザ ジェイ．ディヴィッド グラッドストン インスティテューツ 神経の過度な興奮を緩和する薬剤を識別する方法
AU2009282117B2 (en) 2008-08-11 2016-05-12 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
ES2687469T3 (es) * 2009-09-14 2018-10-25 Banyan Biomarkers, Inc. Marcadores autoanticuerpos para el diagnóstico de traumatismo craneoencefálico
RU2449287C1 (ru) * 2011-03-17 2012-04-27 Государственное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГОУ ВПО СибГМУ Минздравсоцразвития) Способ антенатального прогнозирования последствий перинатальных поражений нервной системы у детей
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
SG11201408626YA (en) 2012-07-03 2015-03-30 Univ Washington Antibodies to tau
KR101582387B1 (ko) * 2013-12-12 2016-01-05 서울대학교산학협력단 뇌전이암 원인종양 진단용 조성물 및 그의 용도
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
RU2568914C1 (ru) * 2014-07-31 2015-11-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский институт акушерства и педиатрии" Министерства здравоохранения Российской Федерации Способ прогнозирования перинатального поражения цнс у недоношенных новорожденных
CN110366558A (zh) 2016-10-28 2019-10-22 班扬生物标记公司 针对泛素c末端水解酶l1(uch-l1)和胶质纤维酸性蛋白(gfap)的抗体及相关方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610330B1 (de) * 1991-10-25 1997-06-18 N.V. Innogenetics S.A. Monoklonale Antikörper gegen das mikrotubulusassoziierte Protein Tau.
DE69318420T2 (de) * 1992-12-14 1999-01-28 Naamloze Vennootschap Innogenetics S.A., Gent Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
JPH06239899A (ja) * 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
JPH10506381A (ja) * 1994-07-29 1998-06-23 イノジェネティックス・ナムローゼ・フェンノートシャップ 特定のサブクラスまたは形態のホスホリレーションされたｔａｕのエピトープに特異的なモノクローナル抗体、それらを分泌するハイブリドーマ、これらの抗体の抗原認識およびそれらの応用
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau

Also Published As

Publication number Publication date
HK1040429A1 (en) 2002-06-07
AU772151B2 (en) 2004-04-08
JP2002524740A (ja) 2002-08-06
EP1112500B1 (de) 2004-09-22
CA2340433A1 (en) 2000-03-16
CN1325491A (zh) 2001-12-05
DE69920487D1 (de) 2004-10-28
JP4624559B2 (ja) 2011-02-02
ES2229817T3 (es) 2005-04-16
AU5974699A (en) 2000-03-27
EP1112500A1 (de) 2001-07-04
HK1040429B (zh) 2005-08-12
DE69920487T2 (de) 2006-03-09
CN101046476A (zh) 2007-10-03
BR9913112A (pt) 2001-05-08
CN101046476B (zh) 2013-04-10
WO2000014546A1 (en) 2000-03-16

Similar Documents

Publication Publication Date Title
ATE277353T1 (de) Tau als marker für frühe schäden des zentralen nervensystems
ATE310955T1 (de) Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten
DE69933661D1 (de) Genomische sequenz des 5-lipoxygenase-aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma
WO2004052175A3 (en) Methods for rapid identification of pathogens in humans and animals
WO2005020785A3 (en) Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
WO2004060278A3 (en) Methods for rapid identification of pathogens in humans and animals
DE50304023D1 (de) Diagnose von Myokardinfarkt und akutem Koronarsyndrom durch Kombination von Markern
HK1073153A1 (en) Systems and methods for identifying organ transplant risk
WO2005052592A3 (en) Methods for diagnosis, stratification, and monitoring of alzheimer’s disease
DK1945622T3 (da) Isotopisk-mærkede benzofuranforbindelser som billeddannelsesmidler til amyloidogene proteiner
ATE424560T1 (de) Marker für neuromyelitis optica
DE60215339D1 (de) Spezifische detektionsmedien für staphylococcus aureus und identifizierungs- und/oder zaehlmethode unter verwendung besagter detektionsmedien
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
DE69609161D1 (de) Amplifikationsoligonukleotide und sonden für borrelia, die mit lyme kranheit assoziiert sind
DE69713498D1 (de) Methode zum nachweis übertragbarer spongiformer enzephalopathien
DE60322848D1 (de) System für kontinuierliche leistungstests
AU2003259222A1 (en) Method of diagnosing alzheimer's disease
WO2003038444A3 (en) Biomarkers of liver function
BR0014150A (pt) Diagnósticos e terapêuticos para osteoporose
WO2004058051A3 (en) Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
MXPA05008793A (es) Metodos para la prediccion de posibilidad de suicidio durante el tratamiento.
WO2003087761A3 (en) Molecular profiling of disease and therapeutic response using phospho-specific antibodies
ATE366260T1 (de) Kalzium-aktivierte kaliumkanäle mit niedriger und mittlerer leitfähigkeit und ihre verwendungen.
WO2004098391A3 (en) Methods for detecting parvovirous infections
DE60127901D1 (de) TCF-1 Nukleotidsequenzvariation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties